Trending Stocks to Own Right Now!
With inflation worries high, and the Federal Reserve tightening rates aggressively, market action has been challenging so far in 2022.
Remember, there are thousands of stocks trading on the NYSE and Nasdaq. But you want to find the very best stocks right now to generate massive gains.
- Dollar General
With recession looming, even Dollar General shoppers are having to tighten their belts. U.S. consumers, the backbone of economic growth, are not as optimistic these days as they usually are.
Dollar General has struggled to top sales and earnings growth rates it posted during the pandemic. Nevertheless, the company boosted its outlook for the year in its latest quarterly report, as shoppers continue to look for deals to mitigate inflation pain
Dollar General said it expect net sales growth of 10% to 10.5% vs. previous views of about 10%. It raised its same-store sales growth forecast to around 3% to 3.5% compared with its previous expectation of 2.5%.
- Centene
Centene is benefiting from a current uptick among health stocks. It has formed a double-bottom pattern, this time with an ideal entry of 87.44.
However it has been meeting resistance at this level. It could form a handle in a few days, lowering the official entry slightly to 87.08.
The relative strength line has just hit a new high, and it remains on a strong long-term uptrend.
Earnings performance is impressive. It holds an EPS Rating of 93 out of 99. **[Earnings grew by an average of 43%](https://research.investors.com/stock-checkup/nyse-centene-corp-cnc.aspx)** over the past three quarters.
Profits are seen ramping up, with 9% growth seen this year and growth of 13% expected in 2023.
The St. Louis-based company is one of the largest Medicaid-based managed care organizations in the country. While Centene primarily provides health care products and services through Medicaid and Medicare, it also works through private insurers.
- Vertex Pharmaceuticals
In Q2, analysts expect the company to earn $3.54 per share on $2.13 billion in sales. Earnings would rise nearly 14% and sales would increase about 19%, according to FactSet.
The company is testing a replacement for pancreatic cells known as islets. Islet cells help produce insulin, but don't function properly in patients with type 1 diabetes. This leads to dangerous spikes in blood sugar. It's important to note, the program is currently on pause in the U.S. while the Food and Drug Administration reviews dosing information.
- Regencell Bioscience
Another rising healthcare bioscience along side Centene and Vertex Pharmaceuticals.
Hong Kong-based Regencell Bioscience is an early clinical stage bioscience company, founded in 2014, is in the business of using traditional Chinese medicine (”TCM”) approach to develop standardized TCM formulas to holistically treat autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD) in children, and infectious diseases which affects the immune system such as COVID-19.
As the company is still in development stage for the TCM treatment for COV19, there isnt much findings available yet except for what the CEO has been pledging.
- Pledged to not draw salary and bonus of more than USD $1 until the Company reaches USD $1 billion market capitalization;
- Will not award share options for himself;
- All directors and employees who were previously granted stock options upon the Company’s IPO have agreed to a further lock-up undertaking for a period of six months after their stock options become vested. As their stock options are set to vest on July 16, 2022, their shares will remain locked up until January 16, 2023.
[https://www.investors.com/research/best-stocks-to-buy-now/?src=A00220]
(https://finance.yahoo.com/news/rgc-ceo-figuratively-putting-money-092700965.html)
With inflation worries high, and the Federal Reserve tightening rates aggressively, market action has been challenging so far in 2022.
Remember, there are thousands of stocks trading on the NYSE and Nasdaq. But you want to find the very best stocks right now to generate massive gains.
- Dollar General
With recession looming, even Dollar General shoppers are having to tighten their belts. U.S. consumers, the backbone of economic growth, are not as optimistic these days as they usually are.
Dollar General has struggled to top sales and earnings growth rates it posted during the pandemic. Nevertheless, the company boosted its outlook for the year in its latest quarterly report, as shoppers continue to look for deals to mitigate inflation pain
Dollar General said it expect net sales growth of 10% to 10.5% vs. previous views of about 10%. It raised its same-store sales growth forecast to around 3% to 3.5% compared with its previous expectation of 2.5%.
- Centene
Centene is benefiting from a current uptick among health stocks. It has formed a double-bottom pattern, this time with an ideal entry of 87.44.
However it has been meeting resistance at this level. It could form a handle in a few days, lowering the official entry slightly to 87.08.
The relative strength line has just hit a new high, and it remains on a strong long-term uptrend.
Earnings performance is impressive. It holds an EPS Rating of 93 out of 99. **[Earnings grew by an average of 43%](https://research.investors.com/stock-checkup/nyse-centene-corp-cnc.aspx)** over the past three quarters.
Profits are seen ramping up, with 9% growth seen this year and growth of 13% expected in 2023.
The St. Louis-based company is one of the largest Medicaid-based managed care organizations in the country. While Centene primarily provides health care products and services through Medicaid and Medicare, it also works through private insurers.
- Vertex Pharmaceuticals
In Q2, analysts expect the company to earn $3.54 per share on $2.13 billion in sales. Earnings would rise nearly 14% and sales would increase about 19%, according to FactSet.
The company is testing a replacement for pancreatic cells known as islets. Islet cells help produce insulin, but don't function properly in patients with type 1 diabetes. This leads to dangerous spikes in blood sugar. It's important to note, the program is currently on pause in the U.S. while the Food and Drug Administration reviews dosing information.
- Regencell Bioscience
Another rising healthcare bioscience along side Centene and Vertex Pharmaceuticals.
Hong Kong-based Regencell Bioscience is an early clinical stage bioscience company, founded in 2014, is in the business of using traditional Chinese medicine (”TCM”) approach to develop standardized TCM formulas to holistically treat autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD) in children, and infectious diseases which affects the immune system such as COVID-19.
As the company is still in development stage for the TCM treatment for COV19, there isnt much findings available yet except for what the CEO has been pledging.
- Pledged to not draw salary and bonus of more than USD $1 until the Company reaches USD $1 billion market capitalization;
- Will not award share options for himself;
- All directors and employees who were previously granted stock options upon the Company’s IPO have agreed to a further lock-up undertaking for a period of six months after their stock options become vested. As their stock options are set to vest on July 16, 2022, their shares will remain locked up until January 16, 2023.
[https://www.investors.com/research/best-stocks-to-buy-now/?src=A00220]
(https://finance.yahoo.com/news/rgc-ceo-figuratively-putting-money-092700965.html)
